Obesity, but not polycystic ovary syndrome, affects circulating markers of low-grade inflammation in young women without major cardiovascular risk factors

Imagem de Miniatura
Arquivos
art_BARCELLOS_Obesity_but_not_polycystic_ovary_syndrome_affects_circulating_2015.PDF (463.27 KB)
Citações na Scopus
17
Tipo de produção
article
Data de publicação
2015
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HELLENIC ENDOCRINE SOC
Autores
BARCELLOS, Cristiano Roberto Grimaldi
DANTAS, Wagner Silva
Citação
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, v.14, n.2, p.251-257, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVE: The aim of this study was to evaluate the influence of polycystic ovary syndrome (PCOS) and obesity on circulating markers of low-grade inflammation-tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6) and high sensitive C-reactive protein (hsCRP)-in young women without major cardiovascular (CV) risk factors (diabetes, dyslipidemia and arterial hypertension). DESIGN: Twenty-five young women with PCOS and 23 eumenorrheic women without major CV risk factors and matched for body mass index (BMI) were studied. They were subdivided according to BMI and PCOS status and comparisons were made between the PCOS and Control groups, regardless of BMI, and between the Obese and Lean groups, regardless of the presence of PCOS. RESULTS: Levels of TNF-alpha, IL-6 and hsCRP were similar between the PCOS group and the Control group (2.1 vs 1.9 pg/ml, p=0.397, 3.8 vs 5.7 pg/ml, p=0.805 and 0.9 vs 0.5 ng/ml, p=0.361, respectively). Levels of TNF-alpha were similar between the obese group and the lean group (2.1 vs 1.9 pg/ml, p=0.444). Levels of IL-6 and hsCRP were higher in the obese group than in the lean group (8.7 vs 2.0, p <0.001 and 1.4 vs 0.2 ng/ml, p <0.001, respectively). CONCLUSION: Obesity, but not polycystic ovary syndrome, affects circulating markers of low-grade inflammation in young women without majorCV risk factors.
Palavras-chave
CV risk, Circulating Markers of low-grade inflammation, Obesity, PCOS
URI
https://observatorio.fm.usp.br/handle/OPI/11893
Referências
  1. [Anonymous], 2002, CIRCULATION, V106, P3143
  2. Azziz R, 2006, J CLIN ENDOCR METAB, V91, P4237, DOI 10.1210/jc.2006-0178
  3. Balistreri CR, 2010, MEDIAT INFLAMM, DOI 10.1155/2010/802078
  4. Barcellos CRG, 2007, ARQ BRAS ENDOCRINOL, V51, P601, DOI 10.1590/S0004-27302007000400015
  5. Barcellos CRG, 2007, ARQ BRAS ENDOCRINOL, V51, P1104, DOI 10.1590/S0004-27302007000700013
  6. Barcellos CRG, 2013, GYNECOL ENDOCRINOL, V29, P370, DOI 10.3109/09513590.2012.743009
  7. Bastard JP, 2006, EUR CYTOKINE NETW, V17, P4
  8. Bautista LE, 2005, J HUM HYPERTENS, V19, P149, DOI 10.1038/sj.jhh.1001785
  9. Ciaraldi TP, 2013, METABOLISM, V62, P1587, DOI 10.1016/j.metabol.2013.07.004
  10. Clearfield Michael B, 2005, J Am Osteopath Assoc, V105, P409
  11. Diamanti-Kandarakis E, 2006, ANN NY ACAD SCI, V1092, P175, DOI 10.1196/annals.1365.015
  12. Erdogan M, 2008, J ENDOCRINOL INVEST, V31, P624
  13. Escobar-Morreale HF, 2003, OBES RES, V11, P987, DOI 10.1038/oby.2003.136
  14. Escobar-Morreale HF, 2001, J CLIN ENDOCR METAB, V86, P3761, DOI 10.1210/jc.86.8.3761
  15. Escobar-Morreale HF, 2011, FERTIL STERIL, V95, P1048, DOI 10.1016/j.fertnstert.2010.11.036
  16. FERRIMAN D, 1961, J CLIN ENDOCR METAB, V21, P1440
  17. Festa A, 2000, CIRCULATION, V102, P42
  18. Genuth S, 2003, DIABETES CARE, V26, P3160
  19. Gonzalez F, 1999, METABOLISM, V48, P437, DOI 10.1016/S0026-0495(99)90100-2
  20. Gonzalez F, 2006, J ENDOCRINOL, V188, P521, DOI 10.1677/joe.1.06579
  21. HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854
  22. Indulekha Karunakaran, 2011, J Diabetes Sci Technol, V5, P982
  23. Jakubowska J, 2008, GYNECOL ENDOCRINOL, V24, P378, DOI 10.1080/09513590802128968
  24. Kahal H, 2013, CLIN ENDOCRINOL, V79, P252, DOI 10.1111/cen.12137
  25. Mathieu P, 2009, HYPERTENSION, V53, P577, DOI 10.1161/HYPERTENSIONAHA.108.110320
  26. Meyer ML, 2012, HUM REPROD UPDATE, V18, P112, DOI 10.1093/humupd/dmr046
  27. Miller AM, 2011, CURR PHARM DESIGN, V17, P1
  28. Mohlig M, 2004, EUR J ENDOCRINOL, V150, P525, DOI 10.1530/eje.0.1500525
  29. Musialik K, 2012, KARDIOL POL, V70, P1237
  30. Olson NC, 2012, J CLIN ENDOCR METAB, V97, P1032, DOI 10.1210/jc.2011-2155
  31. Olszanecka-Glinianowicz M, 2007, EUR J OBSTET GYN R B, V133, P197, DOI 10.1016/j.ejogrb.2006.10.037
  32. Peral B, 2002, J CLIN ENDOCR METAB, V87, P3977, DOI 10.1210/jc.87.8.3977
  33. Popa C, 2007, J LIPID RES, V48, P751, DOI 10.1194/jlr.R600021-JLR200
  34. Ridker PM, 2003, CIRCULATION, V107, P391, DOI 10.1161/01.CIR.0000055014.62083.05
  35. Ridker PM, 2000, CIRCULATION, V101, P1767
  36. Ridker PM, 1998, CIRCULATION, V98, P731
  37. Rocha MP, 2011, GYNECOL ENDOCRINOL, V27, P814, DOI 10.3109/09513590.2010.508852
  38. Rocha MP, 2010, FERTIL STERIL, V93, P1948, DOI 10.1016/j.fertnstert.2008.12.044
  39. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004, FERTIL STERIL, V81, P19, DOI 10.1016/J.FERTNSTERT.2003.10.004
  40. Sarwar N, 2009, DIS MARKERS, V26, P217, DOI 10.3233/DMA-2009-0646
  41. Soares GM, 2009, CLIN ENDOCRINOL, V71, P406, DOI 10.1111/j.1365-2265.2008.03506.x
  42. Tedgui A, 2006, PHYSIOL REV, V86, P515, DOI 10.1152/physrev.00024.2005
  43. Toulis KA, 2011, HUM REPROD UPDATE, V17, P741, DOI 10.1093/humupd/dmr025
  44. TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533
  45. Vgontzas AN, 2006, METABOLISM, V55, P1076, DOI 10.1016/j.metabol.2006.04.002
  46. Villuendas G, 2002, J CLIN ENDOCR METAB, V87, P1134, DOI 10.1210/jc.87.3.1134
  47. WHO, 1999, DEF DIAGN CLASS DI 1
  48. Wild RA, 2010, J CLIN ENDOCR METAB, V95, P2038, DOI 10.1210/jc.2009-2724
  49. Zawadeski JK, 1992, PCOS

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - ODS/03